Pharmaceuticals Acquisitions in Georgia

Amneal Pharmaceuticals has agreed to acquire Saol Therapeutics' Baclofen franchise, including Lioresal and LYVISPAHTM, for approximately $83.5 million in cash plus certain low double-digit royalties. The deal expands Amneal's neurology and specialty portfolio, adds institutional commercial infrastructure ahead of its planned biosimilars launches, and is expected to be accretive to Amneal's 2022 adjusted EBITDA and EPS.

Azurity Pharmaceuticals, majority-owned by NovaQuest Private Equity, has entered into a definitive agreement to acquire Arbor Pharmaceuticals from existing investors including JW Asset Management and KKR. The companies will merge and operate as Azurity, creating a larger specialty pharmaceuticals business with an expanded portfolio across neuroscience, cardiovascular, GI, endocrinology and institutional markets; the transaction is expected to close pending regulatory approvals.

Neogen Corporation has acquired Atlanta-based CAPInnoVet, Inc., a companion animal health company that provides pet medications to the veterinary market. The acquisition gives Neogen entry into the retail parasiticide market and will integrate CAPInnoVet into Neogen's Animal Safety business segment; terms were not disclosed.

Advantage Capital invested $2 million in Watkinsville-based GAXtracts to provide working capital and equipment financing under Georgia’s GARJA program. The growth capital will support facility expansion, the purchase of new equipment and is expected to create 30 new local jobs as GAXtracts scales production of hemp-derived active pharmaceutical ingredients and CBD products.